Systemic therapy for BMs may be effective when the BBB is compromised by the tumor; the response rates for TP and trastuzumab emtansine (T-DM1) for BMs in HER2 breast cancer have been reported to be 11% and 21%, respectively [6,13,14]. This evidence concerns the gene ERBB2 and breast carcinoma.